Home
公司动态及促销
More...

联系方式

销售热线 021-64288051/2 13818234547 021-64869486 13564513910

 

在线留言 咨询 订货
QQ1 QQ2 QQ3
EMail: sale@3bio.cn More

创新的技术，专业的服务

重复劳动大大减少, 工作效率显著提高, 经营状况一目了然，客户体验本质差异化。这就是上海欧为信息科技专为中小贸易及公司及生产企业提供的在线进销存管理系统带来的变化。


系统简介 在线购买 更多联系方式  


Tirzepatide (Synonyms: LY3298176)

Tirzepatide (Synonyms: LY3298176)

Tirzepatide (Synonyms: LY3298176)
产品编号：HY-P1731
分类：分子生物学
品牌：MCE
规格：5mg
单价： ￥5200.00

在线咨询 在线订货 返回上页

​

Tirzepatide  (Synonyms: LY3298176)

Tirzepatide (LY3298176) 是葡萄糖依赖性胰岛素营养多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂，有潜力用于 2 型糖尿病的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务



生物活性

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes[1].

体内研究
(In Vivo)

Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT05412004Eli Lilly and Company
Sleep Apnea|Obesity
June 21, 2022Phase 3
NCT03940742Eli Lilly and Company
Hepatic Insufficiency
July 22, 2019Phase 1
NCT04844918Eli Lilly and Company
Obesity
May 10, 2021Phase 3
NCT03882970Eli Lilly and Company
Type 2 Diabetes Mellitus
April 1, 2019Phase 3
NCT05708859Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Eli Lilly and Company
Type II Diabetes|Atherosclerosis
August 2023Phase 4
NCT04657016Eli Lilly and Company
Obesity|Overweight
March 29, 2021Phase 3
NCT03311724Eli Lilly and Company
Type 2 Diabetes
October 19, 2017Phase 2
NCT05822830Eli Lilly and Company
Obesity|Overweight
April 21, 2023Phase 3
NCT04407234Eli Lilly and Company
Overweight|Obesity|Diabetes Mellitus, Type 2
September 15, 2020Phase 1
NCT04184622Eli Lilly and Company
Overweight|Obesity
December 4, 2019Phase 3
NCT03730662Eli Lilly and Company
Type 2 Diabetes Mellitus
November 20, 2018Phase 3
NCT03322631Eli Lilly and Company
Type 2 Diabetes Mellitus
November 15, 2017Phase 1
NCT05564039Eli Lilly and Company
Type 2 Diabetes
November 30, 2022Phase 4
NCT04004988Eli Lilly and Company
Healthy
August 19, 2019Phase 1
NCT05260021Eli Lilly and Company
Type2 Diabetes|Diabetes Mellitus|Diabetes Mellitus, Type 2|T2D|T2DM (Type 2 Diabetes Mellitus)|Glucose Metabolism Disorders|Endocrine System Diseases|Metabolic Disease
April 13, 2022Phase 3
NCT03375463Eli Lilly and Company
Healthy
December 19, 2017Phase 1
NCT04537923Eli Lilly and Company
Type 2 Diabetes
October 19, 2020Phase 3
NCT05536804Eli Lilly and Company
Overweight|Obesity|Chronic Kidney Disease|Type 2 Diabetes|T2D
February 8, 2023Phase 2
NCT03861052Eli Lilly and Company
Type 2 Diabetes
May 7, 2019Phase 3
NCT03482024Eli Lilly and Company
Renal Insufficiency|End Stage Renal Disease
March 30, 2018Phase 1
NCT04093752Eli Lilly and Company
Type 2 Diabetes
December 9, 2019Phase 3
NCT04166773Eli Lilly and Company
Nonalcoholic Steatohepatitis
November 19, 2019Phase 2
NCT04172987Eli Lilly and Company
Healthy
February 26, 2020Phase 1
NCT03954834Eli Lilly and Company
Type 2 Diabetes Mellitus
June 3, 2019Phase 3
NCT05963022Eli Lilly and Company
Type 2 Diabetes
September 5, 2023Phase 3
NCT05553093Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes Mellitus
March 15, 2022Phase 4
NCT04039503Eli Lilly and Company
Type 2 Diabetes
August 30, 2019Phase 3
NCT05810597Eli Lilly and Company
Healthy
April 3, 2023Phase 1
NCT04847557Eli Lilly and Company
Obesity|Heart Failure With Preserved Ejection Fraction
April 20, 2021Phase 3
NCT05978713Eli Lilly and Company
Healthy
July 31, 2023Phase 1
NCT03987919Eli Lilly and Company
Type 2 Diabetes
July 30, 2019Phase 3
NCT03951753Eli Lilly and Company
Diabetes Mellitus, Type 2
June 28, 2019Phase 1
NCT05696847Eli Lilly and Company
Obesity
February 7, 2023Phase 1
NCT05912621Stanford University|Eli Lilly and Company
Obesity|Overweight and Obesity|Overweight
June 2023Phase 2
NCT04255433Eli Lilly and Company
Type 2 Diabetes Mellitus
May 29, 2020Phase 3
NCT04311411Eli Lilly and Company
Obesity|Overweight
August 24, 2020Phase 1
NCT04660643Eli Lilly and Company
Obesity|Overweight
March 29, 2021Phase 3
NCT05582096Eli Lilly and Company
Overweight|Obesity
November 11, 2022Phase 1
NCT05556512Eli Lilly and Company
Obesity|Overweight
October 11, 2022Phase 3
NCT04050553Eli Lilly and Company
Diabetes Mellitus, Type 2|Hypoglycemia
February 24, 2020Phase 1
NCT05433584Eli Lilly and Company
Type 2 Diabetes
August 1, 2022Phase 4
NCT04050670Eli Lilly and Company
Healthy
September 13, 2019Phase 1
NCT04311424Eli Lilly and Company
Healthy
July 28, 2020Phase 1
NCT04657003Eli Lilly and Company
Type 2 Diabetes|Overweight|Obesity
March 29, 2021Phase 3
NCT02759107Eli Lilly and Company
Healthy|Type 2 Diabetes Mellitus (T2DM)
May 11, 2016Phase 1
NCT05706506Eli Lilly and Company
Type 2 Diabetes|Diabetes Mellitus, Type 2
March 8, 2023Phase 4
NCT04081337Eli Lilly and Company
Obesity
July 9, 2020Phase 1
NCT04235959Eli Lilly and Company
Diabetes Mellitus, Type 2
October 21, 2020Phase 1
NCT05766358Pennington Biomedical Research Center
Weight Loss|Weight Gain|Obesity
October 6, 2022
NCT03861039Eli Lilly and Company
Type 2 Diabetes Mellitus
March 30, 2019Phase 3
NCT05024032Eli Lilly and Company
Obesity|Overweight|Metabolism and Nutrition Disorder
September 1, 2021Phase 3
NCT05691712Eli Lilly and Company
Diabetes Type 2|Diabetes Mellitus|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases
February 5, 2023Phase 3
NCT05659368Ospedale San Raffaele
Wolfram Syndrome
January 2023Phase 2
NCT03131687Eli Lilly and Company
Type 2 Diabetes Mellitus
May 24, 2017Phase 2
分子量

4813.45

性状

固体

Formula

C225H348N48O68

CAS 号
Sequence Shortening

Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2

中文名称

替尔泊肽

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder-80°C2 years
-20°C1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro: 

DMSO 中的溶解度 : 50 mg/mL (10.39 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM0.2078 mL1.0388 mL2.0775 mL
5 mM0.0416 mL0.2078 mL0.4155 mL
10 mM0.0208 mL0.1039 mL0.2078 mL
 查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

扫码获得
动物溶解方案

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

 mg/kg

动物的平均体重

 g

每只动物的给药体积

 μL

动物数量

 只
由于实验过程有损耗，建议您多配一只动物的量
 
纯度 & 产品资料

纯度： 99.64%

Data Sheet (595 KB)SDS (418 KB)

COA (164 KB)RP-HPLC (111 KB)MS (222 KB)

产品使用指南 (1538 KB)
参考文献

Tirzepatide 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂浓度溶剂体积质量1 mg5 mg10 mg25 mg
DMSO1 mM0.2078 mL1.0388 mL2.0775 mL5.1938 mL
5 mM0.0416 mL0.2078 mL0.4155 mL1.0388 mL
10 mM0.0208 mL0.1039 mL0.2078 mL0.5194 mL

选择3bio,选择成功